HR Execs on the Move

Toronto Academy of Dentistry

www.tordent.com

 
Toronto Academy of Dentistry is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Women`s Health USA

Women`s Health USA is a provider of value-based care and practice management services to more than 600 women`s health providers across the U.S. With a unique focus on women, Women`s Health USA is an influential player in the development of new cost effective, value-based modes of care delivery. For 22 years, the company has successfully implemented innovative growth strategies and driven streamlined operational costs, payer alignment, ancillary services development, brand development strategies and risk management services. Its unique partnership model enables women`s health groups to operate independently, while leveraging the resources and influence of a national organization.

Olean General Hospital

Olean General Hospital/Bradford Regional Medical Center is a healthcare provider offering primary and specialty care to residents in southwestern New York state and northwestern Pennsylvania.

HPS Group

HPS Group is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NovaSom

NovaSom is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cleveland Biolabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.